IRF4 Fusion is an inclusion criterion in 2 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for intravascular large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 2 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 Fusion and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for ALK-positive large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and ALK-positive large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma activated B-cell type, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for germinal center B-cell-like diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IRF4 Fusion is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 Fusion and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].